ArticleNature communications2019
Rewiring carbon metabolism in yeast for high level production of aromatic chemicals.
Article in Nature communications, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 131 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
131 citing papers in PubMed, 328 citations in OpenAlex.
- Shikimate crosstalk enables record-level homogentisic acid production inSynthetic and systems biotechnology · 2026Article
- Article
- Valorization of xylose mother liquor into salidroside by engineeredSynthetic and systems biotechnology · 2026Article
- Enzyme promiscuity-driven co-production of flavonoid 7-Synthetic and systems biotechnology · 2026Article
- Evolution and Active Learning Identify Terminal and Distal Determinants for Improved TAL in P-Coumaric Acid Production.Biotechnology and bioengineering · 2026Article
- Machine-Learning-Assisted Pathway Optimization in Large Combinatorial Design Spaces: A p-Coumaric Acid Case Study.ACS synthetic biology · 2026Article
- Metabolic Engineering Strategies for Flavonoid Biosynthesis in Saccharomyces cerevisiae: Current Advances and Future Perspectives.Biotechnology and bioengineering · 2026Review
- Construction of a Saccharomyces Cerevisiae Cell Factory for Shikimate Production through Precise Regulatory Strategies.Applied biochemistry and biotechnology · 2026Article
- Synthesis of Amines for Active Pharmaceutical Ingredients Using the Whole-Cell Factory Saccharomyces Cerevisae.Chembiochem : a European journal of chemical biology · 2026Review
- Methanol-based biosynthesis of p-coumaric acid by engineered Pichia pastoris.Bioresources and bioprocessing · 2026Article
- Combination of enzyme engineering and quorum sensing system for efficient de novo biosynthesis of β-arbutin inSynthetic and systems biotechnology · 2026Article
- Article
- Engineering yeast for sustainable bioproduction of tryptophan-derived aromatic compounds.FEMS yeast research · 2026Review
- Efficient, complete biosynthesis of isoflavonoid calycosin-7-glucoside by metabolically engineered yeast cell factories.Frontiers in bioengineering and biotechnology · 2026Article
- Optimizing L-Tryptophan Production inJournal of microbiology and biotechnology · 2025Article
- Metabolic engineeringSynthetic and systems biotechnology · 2025Article
- Engineering yeast peroxisome assembly enables the increased production of acetyl-CoA and its derived 5-deoxyflavonoids.Nature communications · 2025Article
- Engineering chronological lifespan toward a robust yeast cell factory.Proceedings of the National Academy of Sciences of the United States of America · 2025Article
- Balancing Cell Growth and Product Synthesis for Efficient Microbial Cell Factories.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Review
- The complete synthetic pathway of echinacoside from Cistanche deserticola and its de novo biosynthesis in yeast.Plant communications · 2025Article
71 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The production of bioactive plant compounds using microbial hosts is considered a safe, cost-competitive and scalable approach to their production. However, microbial production of some compounds like aromatic amino acid (AAA)-derived chemicals, remains an outstanding metabolic engineering challenge. Here we present the construction of a Saccharomyces cerevisiae platform strain able to produce high levels of p-coumaric acid, an AAA-derived precursor for many commercially valuable chemicals. This is achieved through engineering the AAA biosynthesis pathway, introducing a phosphoketalose-based pathway to divert glycolytic flux towards erythrose 4-phosphate formation, and optimizing carbon distribution between glycolysis and the AAA biosynthesis pathway by replacing the promoters of several important genes at key nodes between these two pathways. This results in a maximum p-coumaric acid titer of 12.5 g L
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.